Publication|Articles|September 24, 2025
Optimizing Long-Acting Injectable Administration for Patients Living With Schizophrenia
Advertisement
This educational resource was sponsored by Johnson & Johnson.
In this educational resource, experts from a pharmacy and hospital provide an overview of their respective long-acting injectable antipsychotic programs, which are designed to help improve access and adherence to medications for people living with a severe and persistent mental illness like schizophrenia.
Articles in this issue
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Near Low–Income Medicare Beneficiaries Face More Affordability Problems Than Other Income Groups
2
Trump Administration Flags Potential Link Between Prenatal Acetaminophen Use, Autism
3
Subtle Brain Changes May Drive Disability in Multiple Sclerosis Beyond Visible Lesions
4
Nicotinamide Reduces New Skin Cancer Risk in Large Veteran Study
5